|Day Low/High||221.84 / 226.38|
|52 Wk Low/High||215.78 / 344.00|
Dozens of beaten-up stocks could see tax-loss selling into the end of the year; here's a preview of some that could make up the next Tax Loss Selling Portfolio.
Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during first trimester Data show pregnancy...
DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term data from the SHINE study demonstrate improvements in or...
CAMBRIDGE, Mass., Sept.
- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018.
Results of a safety review convinces Biogen to shut down the trials of its experimental Alzheimer's treatment.
Discontinuation of studies based on Data Safety Monitoring Board recommendation
Data highlight benefits of TYSABRI ® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognition An analysis of data from the TYSABRI Observational Program (TOP)...
TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatment Latest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and Alkermes' investigational treatment, diroximel...
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
New SMA STAT genetic test reduces time to provide results from 21 to four days to aid in clinical care Early treatment of SMA has been shown to slow disease progression and improve or stabilize loss of motor function SMA Identified program offers genetic...
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --
— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate — DUBLIN,...
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.
The drugmaker reports second-quarter results that beat analysts' forecasts and raises its guidance for the remainder of the year on strong demand for its multiple sclerosis and other disease-fighting medications.
U.S. stock futures rise ahead of earnings reports from a number of corporate heavyweights and after the White House and congressional negotiators reach a budget deal that will lift the government's debt limit; Coca-Cola, Snap, Visa and Harley-Davidson are among the companies reporting earnings on Tuesday; Apple reportedly is in talks to buy Intel's modem chip business for $1 billion.
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
- New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently
The firm now has a neutral rating on Biogen based on data from a new neurologist survey.
Buyers have returned in recent months and the stock could be ready to rise.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.